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Background: Psychotic depression (PD) is a severe disabling disorder with considerable morbidity and mortality.
Electroconvulsive therapy and pharmacotherapy are each efficacious in the treatment of PD. Expert guidelines
recommend the combination of antidepressant and antipsychotic medications in the acute pharmacologic
treatment of PD. However, little is known about the continuation treatment of PD. Of particular concern, it is not
known whether antipsychotic medication needs to be continued once an episode of PD responds to
pharmacotherapy. This issue has profound clinical importance. On the one hand, the unnecessary continuation of
antipsychotic medication exposes a patient to adverse effects, such as weight gain and metabolic disturbance. On
the other hand, premature discontinuation of antipsychotic medication has the potential risk of early relapse of a
severe disorder.
Methods/design: The primary goal of this multicenter randomized placebo-controlled trial is to assess the risks and
benefits of continuing antipsychotic medication in persons with PD once the episode of depression has responded
to treatment with an antidepressant and an antipsychotic. Secondary goals are to examine age and genetic
polymorphisms as predictors or moderators of treatment variability, potentially leading to more personalized
treatment of PD. Individuals aged 18-85 years with unipolar psychotic depression receive up to 12 weeks of open-
label treatment with sertraline and olanzapine. Participants who achieve remission of psychosis and remission/near-
remission of depressive symptoms continue with 8 weeks of open-label treatment to ensure stability of remission.
Participants with stability of remission are then randomized to 36 weeks of double-blind treatment with either
sertraline and olanzapine or sertraline and placebo. Relapse is the primary outcome. Metabolic changes are a
secondary outcome.
Discussion: This trial will provide clinicians with much-needed evidence to guide the continuation and
maintenance treatment of one of the most disabling and lethal of psychiatric disorders.
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Major depression with psychotic features (psychotic de-
pression; PD) is a severe, potentially fatal disorder with a
high risk of relapse and recurrence [1,2]. Older adults
are at greatest risk of PD, with up to 45% of older
inpatients with major depression having psychotic
features [3,4]. Electroconvulsive therapy (ECT) and
pharmacotherapy are each efficacious in the treatment
of PD [5,6]. Several factors influence the choice of treat-
ment, including patient preference, clinical acuity, past
history of treatment response, side effect profile, and
availability of ECT.
When pharmacotherapy is selected, expert guidelines,
supported by meta-analytic evidence, recommend a
combination of antidepressant and antipsychotic
medications for acute treatment [7-9]. However, little is
known about the continuation and maintenance treat-
ment of PD. Once an episode of major depression
responds to antidepressant medication, the antidepres-
sant needs to be continued to prevent relapse and recur-
rence of depression [10]. However, it is not known
whether antipsychotic medication needs to be continued
once an episode of PD has responded to combined
antidepressant-antipsychotic treatment. This issue is of
profound clinical importance: on the one hand, prema-
ture discontinuation of antipsychotic medication has the
potential risk of relapse of a severe, life-threatening dis-
order; on the other hand, the unnecessary continuation
of antipsychotic medication exposes a patient to poten-
tially serious adverse effects.
There are few data on the relation between discontinu-
ation of antipsychotic medication and relapse of PD. In a
chart review of persons with PD who had responded to
pharmacotherapy, Aronson et al. [11] found that ap-
proximately 35% of relapses occurred following the dis-
continuation of antipsychotic medication in persons who
continued to take antidepressant medication. The only
prospective study of antipsychotic discontinuation in PD
found a frequency of relapse of 27% over 8 months in 30
mid-life adults who had recovered with combined fluox-
etine and perphenazine [12]; the findings of this study
are, however, limited by its open and uncontrolled de-
sign, the relatively small number of subjects, and the ab-
sence of older patients who, based on studies of non-PD,
may conceivably be at greater risk of relapse [13]. In
contrast to these discontinuation data, three small open-
label studies suggest that patients with PD who are
maintained on the treatment to which they responded
may have only a 0-6% rate of relapse over 12 months
[14-16].
The recently completed Study of the Pharmacotherapy
of Psychotic Depression (STOP-PD) [17] was the first
NIMH-funded randomized controlled trial (RCT) to
examine the efficacy and tolerability of combinationpharmacotherapy using a serotonergic antidepressant
and a second generation antipsychotic medications in
the acute treatment of PD. The combination of sertraline
and olanzapine was significantly more efficacious than
olanzapine monotherapy. The two treatments had com-
parable tolerability. Nevertheless, both treatments were
associated with an increase in weight and lipids over the
12-week study. The primary goal of STOP-PD II
(‘Sustaining Remission of Psychotic Depression’) is to as-
sess the benefits and risks of continuing antipsychotic
medication in younger and older patients with PD, once
the episode of psychotic depression has responded to
treatment with sertraline and olanzapine. This goal will
be addressed through a 36-week double blind RCT, in
which placebo is substituted for olanzapine in half the
study group, following a period of sustained remission.
The study provides the unique opportunity to systemat-
ically assess the effect of antipsychotic discontinuation
on olanzapine-related weight gain and metabolic dis-
turbance. Olanzapine was chosen because it is the only
antipsychotic medication with established efficacy in
combination therapy in both younger and older persons
with psychotic depression. Additional aims of the study
are to examine age and genetic polymorphisms as
predictors/moderators of treatment variability. The pur-
pose of this article is to describe and discuss selected
aspects of the rationale, design, and methodology of
STOP-PD II, in order to highlight research and clinical
issues that are pertinent to the longer-term pharmaco-
logic management of PD. The study has been approved
by the local review boards of the four participating
sites: University Health Network, Toronto; University
of Massachusetts Medical School; University of Pittsburgh
School of Medicine; and Weill Cornell Medical College.
Quality assurance and safety issues are overseen by a Data
and Safety Monitoring Board appointed by the National
Institute of Mental Health.
Methods/design
Overview of design
The study has 3 phases: acute, stabilization, and
randomized. We plan to enroll 392 patients (n = 196
aged 18-59 years and n = 196 aged ≥60 years) with
Structured Clinical Interview for DSM-IV-TR [18]
(SCID)-defined non-bipolar major depression with
psychotic features (delusions, with or without
hallucinations) across 4 sites into open-label treatment
with the combination of sertraline (target dose of 150-
200 mg/day) and olanzapine (target dose of 15-20 mg
/day). Participants will continue with open-label
sertraline and olanzapine for an 8-week stabilization
phase if they no longer have delusions and hallucinations
and either a) have a 17-item Hamilton Depression Rat-
ing Scale (HAM-D) [19] score of ≤10 for 2 consecutive
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improved’ or ‘much improved’ on the Clinical Global
Impression (CGI) Scale [20] and have a HAM-D score
of 11-15 with ≥50% reduction in their baseline HAM-D
score by the end of the acute phase (‘near-remission’).
While the acute phase of the study can last a maximum
of 12 weeks, participants enter the stabilization phase as
soon as they meet full-remission criteria. Participants
who continue to meet full-remission or near-remission
criteria and have a Mini-Mental State Examination
(MMSE) [21] score of ≥24 at the end of the stabilization
phase enter the 36-week RCT. Participants are
randomized under double-blind conditions to either
continue olanzapine or switch from olanzapine to
placebo following a 4-week placebo-controlled taper of
the olanzapine. All participants take open-label sertraline
for the duration of the RCT. Relapse is the primary
outcome.Rationale for aspects of the design
Duration of acute treatment
Although most studies of the acute treatment of PD
have been of 6-8 weeks duration [6,9], a maximum of
12 weeks of acute treatment is more suitable for this
study for several reasons. First, one of the goals of the
acute phase is to maximize the chance of achieving re-
mission of delusions and antidepressant response, in
order for participants to enter the RCT. In STOP-PD,
one-third of participants who experienced remission
with combined sertraline and olanzapine did not do so
until between weeks 6 and 12 of treatment. Second,
studies of 6-8 weeks typically use one cross-sectional as-
sessment of ≥50% decrease in severity of depression as
the primary outcome criterion. The acute treatment out-
come criterion used in this study requires a longer
period of observation. On the other hand, the decision
to limit acute treatment to a maximum of 12 weeks is
based on funding considerations and the fact that
patients who do not experience remission of psychosis
and at least substantial improvement in depression
following 12 weeks of intensive antidepressant-
antipsychotic treatment should probably be considered
for additional or alternative treatment.Duration of stabilization phase
There are no data, and there is no consensus among
experts, about how long to continue antipsychotic medi-
cation, once an episode of PD has responded to combin-
ation pharmacotherapy. However, a survey of 50 experts
in the treatment of late-life depression found that the
majority would not recommend stopping antipsychotic
medication immediately after remission of PD [22]. In
the absence of data to the contrary, we believe that it isprudent to allow for a period of stability of remission of
psychosis prior to withdrawal of the antipsychotic.
Discontinuation design
The primary aim of this study is to assess whether
olanzapine, in combination with antidepressant medica-
tion, prevents relapse of PD. This question can be
addressed through a RCT, in which placebo is
substituted for olanzapine in half the study participants
at a fixed point in time. We also considered a placebo-
controlled sequential discontinuation design, whereby
placebo is substituted for olanzapine at different time
points. Whilst a sequential discontinuation design could
provide additional information about how long to con-
tinue olanzapine once an episode of PD has remitted, it
would require many more study participants than the
design that we propose, and would therefore be more
challenging in terms of recruitment and much more
costly than the current study.
Duration of the RCT
Limited data from naturalistic studies of PD suggest that
when antipsychotic medication is discontinued, the first
3 months after discontinuation is the period of greatest
risk of relapse [11]. The choice of 36 weeks for the RCT
therefore: a) covers the period of greatest risk of relapse
of PD following the discontinuation of the antipsychotic,
yet allows for a period of observation beyond that time,
b) saves on the cost that would be associated with a
longer study, and c) allows the study to be completed
within 5 years in the four collaborating sites.
Duration of antipsychotic taper
In Rothschild et al’s [12] open-label study of the with-
drawal of antipsychotic medication in PD, antipsychotic
medication was tapered over a period of 4 weeks. No pa-
tient experienced discontinuation side effects or re-
emergence of psychosis during the 4-week taper.
Stratification by Age
PD is prevalent in older adults with major depression
[3,4,23]. Age-related pharmacodynamic and pharmaco-
kinetic changes may result in age-related differences in
treatment efficacy and tolerability [24]. It is therefore
important to include a sufficient number of older per-
sons in order to examine the relation between age, ef-
ficacy, tolerability, and safety.
Remission criteria to enter the RCT
Studies of major depression have found that experien-
cing only partial improvement in depressive symptoms
may increase the risk of subsequent relapse of depres-
sion [25]. We therefore believe that, in addition to ex-
periencing full remission of psychosis, participants
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ment in their depressive symptoms prior to changes
being made to the treatment to which they responded.
Given that patients in this study continue with an anti-
depressant throughout the RCT, and may therefore con-
tinue to experience improvement in depression beyond
the acute/stabilization phases of treatment, we include
persons with substantial improvement in depressive
symptoms, even though the symptoms may not have
reached the conventional < 8-10 HAM-D cut point for
remission used in studies of non-psychotic depression;
this approach reflects ‘real world’ clinical practice.
MMSE score ≥24 to enter the RCT
Dementia can be associated with depressive and psych-
otic symptoms that respond differently to pharmacother-
apy from major depressive disorder with psychotic
features. As described in the Eligibility section below,
persons with evidence of clinically significant cognitive
decline preceding the index episode of PD, a marker for
current or incipient dementia, are excluded from the
study. In addition, any participant with a MMSE score
<24 at the end of the stabilization phase is excluded
from participation in the RCT, since poor cognitive per-
formance at that stage of the study cannot be explained
by depression or psychosis.
Hypotheses and exploratory aims
Primary hypothesis
H1.The combination of sertraline and olanzapine will be
associated with less risk of relapse than the combination
of sertraline and placebo.
Secondary hypotheses
H2. The combination of sertraline and olanzapine will
be associated with higher weight, higher total choles-
terol, and higher triglycerides compared with the com-
bination of sertraline and placebo in the randomized
phase.
H3. Older age will be associated with less weight gain
than younger age during the open-label phase.
Exploratory aims
i) Explore older age as a moderator of change in weight,
lipids, and insulin resistance during the randomized
phase. ii) Explore the association of selected genetic
polymorphisms with: a) response, b) relapse, and c)
weight, lipids, and insulin resistance during the open-
label and randomized phases of the study.
Recruitment and eligibility
Patients are recruited from inpatient units, outpatient
programs, and affiliated community hospitals of the 4
academic healthcare centers that participated in STOP-PD (i.e., the medical centers of Cornell University, the
University of Massachusetts, University of Pittsburgh,
and University of Toronto). Inclusion/exclusion criteria
are described in Table 1. Several of these criteria deserve
specific mention. First, participants are required to have
delusions, whether or not hallucinations are present.
This increases diagnostic precision, since psychotic
patients with hallucinations alone are more likely to be
suffering from another disorder, such as schizophrenia,
schizoaffective disorder, brief psychotic disorder, or a
toxic-metabolic encephalopathy, as a cause of their
psychotic symptoms [26]. Second, given that the validity
of a study of psychotic depression rests on the presence
of delusions (as opposed to other abnormal beliefs such
as overvalued ideas, obsessions, or anxious worries)
participants in STOP-PD II must score >2 on at least
one of the three conviction items of the Delusion As-
sessment Scale (DAS) [27]; that is, they must be certain
that the delusional belief is true and not modify the be-
lief or consider alternative explanations in response to
reality testing by the interviewer. Third, persons with de-
mentia are excluded because delusions and depression
may be symptomatic manifestations of dementia [28].
The pathophysiology, treatment response, and course of
these symptoms of dementia may differ from those of
PD. In addition, non-delusional confabulations are a fre-
quent symptom of dementia and may be difficult to reli-
ably distinguish from delusions [28]. Moreover,
dementia may affect a person’s ability to reliably and ac-
curately report the presence and course of symptoms,
which could affect the validity of ratings of outcome. Fi-
nally, persons with Type 1 diabetes mellitus are at risk of
ketoacidosis if they become hyperglycemic, whereas
ketoacidosis is a very rare event in persons with Type 2
diabetes [29]. Therefore, to avoid the potential risk of
ketoacidosis precipitated by olanzapine-associated
hyperglycemia, persons with Type I diabetes are
excluded from the study.
Informed consent
PD may impair a person’s capacity to consent to partici-
pate in a research study. To recruit people who are rep-
resentative of the population being studied, the study
allows people who do not have the capacity to give
informed consent to participate in the open-label phase
of the study (acute and stabilization). Capacity is
determined by either an assessment conducted by a
licensed mental healthcare professional who is independ-
ent of the study or by administration of the MacArthur
Competence Assessment Tool for Clinical Research
(MacCAT-CR) [32]. The MacCAT-CR is a semi-
structured interview for assessment of capacities related
to consent to research; it has been found to be a valid
measure of capacity to consent in persons with
Table 1 STOP-PD II Inclusion and Exclusion criteria
Inclusion criteria
1) Aged 18-85 years, inclusive
2) Diagnosis: DSM-IV non-bipolar major depression with psychotic
features, established through both a clinical interview by a research
psychiatrist and the subsequent administration of the SCID-IV by a
research associate
3) Score of ≥3 on the delusion severity item of the SADS (‘delusion
definitely present’), with or without hallucinations on the SADS
hallucination item
4) Score of >2 on any of the three conviction items of the DAS (the
participant is certain a belief is true and does not change the belief
in response to reality testing by the interviewer);
5) 17-item Ham-D score of >21.
Exclusion criteria
1) Current or lifetime DSM-IV criteria for: schizophrenia, schizoaffective
disorder or other psychotic disorder, mental retardation, or meeting
DSM-IV criteria for current brief psychotic disorder, body
dysmorphic disorder, or obsessive-compulsive disorder
2) Current or lifetime DSM-IV criteria for bipolar affective disorder
3) History of DSM-IV defined substance abuse or dependence,
including alcohol, within the last three months
4) DSM-IV defined Alzheimer’s dementia, vascular dementia, or
dementia due to other medical conditions, or a history of clinically
significant cognitive impairment prior to the index episode of
depression, and/or a mean score of ≥4 on the 26-item IQCODE.
The IQCODE will be used to screen for clinically significant
cognitive decline that began prior to the index episode of PD (a
cut score of 4 has been found to have a sensitivity of 84-93% and
specificity of 88-94% in screening for dementia in general,
psychiatric, and medical populations of older adults [30,31]
5) Type 1 diabetes mellitus (defined as insulin-dependent diabetes
mellitus with onset < 35 years of age and/or diabetes mellitus that
has been complicated by a prior documented episode of
ketoacidosis)
6) Acute or unstable medical illnesses (e.g., delirium; metastatic
cancer; unstable diabetes, decompensated cardiac, hepatic, renal or
pulmonary disease; stroke; or myocardial infarction) within the last
three months; current abnormal serum free T4; current abnormally
low serum vitamin B12 or folic acid level; medical conditions and/
or medications for which psychotic or depressive symptoms can be
a direct manifestation (e.g. Cushing’s disease, high-dose systemic
corticosteroids, L-dopa); neurological disease associated with
extrapyramidal signs and symptoms (e.g. Parkinson’s disease);
epilepsy, if the person has had one or more grand mal seizures in
the past 12 months
7) The need for treatment with any psychotropic medications other
than sertraline, olanzapine, or lorazepam; or with an anticonvulsant
medication with mood-stabilizing properties (carbamazepine,
lamotrigine, valproic acid)
8) Current pregnancy or a plan to become pregnant during the
duration of the study in woman of childbearing age; breast-feeding
in woman with infants
9) A clearly documented history of being unable to tolerate sertraline
and/or olanzapine, including having had an untoward previous
reaction to sertraline such as significant bradycardia (heart rate of
<50 bpm) or development of the syndrome of inappropriate
antidiuretic hormone secretion with a serum sodium of 129 mmol/
L or below
10) History of non-response of the index episode of PD to at least a 6-
week trial of ≥150 mg/day sertraline combined with≥ 15 mg/day
olanzapine
Table 1 STOP-PD II Inclusion and Exclusion criteria
(Continued)
11) Patients showing ongoing improvement in the index episode of
PD with treatment, other than sertraline and olanzapine, initiated
prior to the study
12) Sufficiently ill to require immediate ECT (e.g., imminent risk of
suicide, refusing to eat or severe malnutrition, catatonic)
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if they assent to participate and informed consent is
obtained from a surrogate decision maker. Subjects who
are eligible for the randomized phase must have achieved
sustained remission or near remission by the end of sta-
bilization and therefore must be capable of giving their
own informed consent to participate in the RCT.
Treatment regimen
Acute and stabilization (open-label) phases
The only psychotropic medications allowed in the study
are i) olanzapine, ii) sertraline, iii)‘as needed’ lorazepam
or stable doses of other benzodiazepines if they were
being taken prior to study entry and the participant is
not able to cross-taper to lorazepam, and iv) ‘as needed’
benztropine. When participants meet remission criteria,
they continue with open-label sertraline and olanzapine
during the 8-week stabilization phase. Since the goal of
the stabilization phase is to consolidate stability of re-
mission, adjustment of the doses of study medications is
allowed, if necessitated by clinical worsening or signifi-
cant side effects. Because sustained remission of psych-
osis during the stabilization phase is required for
eligibility for the RCT, participants leave this phase if
they experience a relapse of delusions or hallucinations
during this time as determined by SCID interview.
Randomized phase
Participants who continue to meet the study’s remission
criteria at the end of the stabilization phase are ran-
domly allocated to either continue olanzapine or switch
from olanzapine to placebo. All participants take open-
label sertraline for the duration of the RCT. The goal is
to maintain sertraline at the same acute dose as the one
prescribed at the time of randomization to the RCT. Be-
cause participants have taken sertraline for 12-20 weeks
before entering the RCT, we anticipate that the dose of
sertraline will rarely need to be adjusted in the RCT be-
cause of adverse effects. However, a reduction of the
dosage of sertraline is allowed if the site PI agrees. In
contrast, an increase in dose of sertraline is not permit-
ted at any time during the RCT, because it will confound
testing of the primary hypothesis. Similarly, the goal is
to maintain olanzapine/placebo at the same acute dose
as the one prescribed at the time of randomization to
Acute Phase (N=392) 
Open-Label Sertraline and Olanzapine 
(up to 12 weeks) 
50% Meet 
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placebo is permitted, if necessitated by adverse effects or
clinical worsening during the RCT, following discussion
with the site PI. The rationale for allowing a change in
olanzapine/placebo dose is that the primary aim of the
study is to assess whether olanzapine, administered within
a clinically relevant dose range, prevents relapse, not whe-
ther a specific dose of olanzapine prevents relapse.Stabilization Phase (N =196) 
Open-Label Sertraline and Olanzapine 
(8 weeks) 
Remission/Near-Remission Criteria 
10% Relapse  
or Withdraw 
Discontinuation RCT (N=176) 
Open-Label Sertraline plus Blinded Study Medication
(Olanzapine or Placebo) 
(36 weeks) 
Figure 1 STOP-PD II: study design and subject flow.Relapse criteria
Relapse is the primary outcome. Relapse criteria are
broad, to reflect a range of clinically relevant outcomes
of PD. Declaring relapse requires at least one of the
following: 1) symptoms of DSM-IV major depression; 2)
17-item HAM-D score of ≥18; 3) re-emergence of
SCID-rated psychosis (delusions or hallucinations) and a
score of ≥3 on the Schedule of Affective Disorders and
Schizophrenia (SADS) [33] delusion or hallucination se-
verity items (delusion/hallucination ‘definitely present’);
4) other significant clinical worsening, defined as: i) sui-
cide plan or suicide attempt at any time, ii) development
of SCID-rated symptoms of mania or hypomania, or iii)
psychiatric hospitalization for depression, psychosis,
suicidality, or mania/hypomania, regardless of the dur-
ation of these symptoms. These relapse criteria reflect a
clinical deterioration for which most clinicians would
consider a change of treatment. Even though patients
with a history of bipolar disorder will not be allowed to
enter the study, mania or hypomania is included as an
outcome variable because onset of PD in younger adults
may predict subsequent development of bipolar disorder
[1,2]. Participants with relapse will leave the study and
be treated under usual care conditions.Sample estimates
Of the 392 subjects recruited to the acute phase of the
study, we anticipate that 196 (50%) will achieve remis-
sion or near-remission as defined above. Based on
STOP-PD pilot stabilization data and findings of the
study by Rothschild et al. [12], we estimate that approxi-
mately 10% of acute phase full/near-remitters will not
complete the 8-week stabilization phase, either because
of relapse or discontinuation. Thus, we predict that 176
participants will be randomized (Figure 1).Measures and schedule of study visits
Primary clinical measures
Pertain to the study’s aims and hypotheses or eligibility
criteria. They are the SCID-IV, GRID version of the 17-
item HAM-D [34], DAS, delusion and hallucination
items of the SADS, Scale for Suicidal Ideation (SSI) [35],
CGI, IQCODE [36], and MMSE (Table 2).Secondary clinical measures
Anxiety symptoms, medical burden, executive dysfunc-
tion, psychomotor change, and ‘treatment resistance’
during an index episode of depression have each been
associated with increased risk of relapse/recurrence of
major depression [44-48]. These variables are therefore
included as covariates in the Cox model examining risk
of relapse. In addition, given the age range of study
participants, selected cognitive tests (delayed recall, psy-
chomotor speed, and cognitive flexibility) that target
previously described impairments in PD [49] and late-
life depression [50] are administered at entry in to the
RCT to help characterize the RCT sample.
Measures of Non-metabolic safety
Are the UKU Side Effects Scale [51], Simpson Angus
Scale [52] to measure drug-associated parkinsonism,
Barnes Akathisia Scale [53], Abnormal Involuntary
Movement Scale [54] to measure tardive dyskinesia,
orthostatic hypotension, and frequency of falls.
Anthropometric measures
The selection of anthropometric measures and metabolic
parameters is based on consensus recommendations
regarding the clinical monitoring of patients treated with
atypical antipsychotics [55]. Body mass index (BMI) and
Table 2 STOP-PD II schedule of events: acute and stabilization phases and randomized controlled trial (RCT)
Instrument Baseline Acute phasea (week)
(4-12 wks in duration)
Stabilization phase
(week)
Discontinuation RCT (week)
4 8 12b 4 8 1 2 3 4 5 6 7 8 12 16 20 24 28 32 36c
SCID x x
Clinical Ratingsd x x x x x x x x x x x x x x x x x x x x x
Weight & Waist Circumference x x x x x x x x x x x x x x x x x x x x x
Height x
Metabolic Labs x x x x x x x x x
Drug Plasma Levels x x x x x
Genetic Testing x
Baseline Physicale x
Vital Signs x x x x x x x x x x x x x x x x x x x x x
Anxietyf x x
Medical Burdenf x x
Psychomotor Changef x x
Cognitiong x x
Treatment Resistanceh x
Quality of Lifei x x x
EPSE Ratings x x x x x x x x x x x x x x x
Best Guess Formj x
Pill Count x x x x x x x x x x x x x x x x x x x x
a The duration of the Acute Phase is variable and can last between 4 and 12 weeks, depending on time to response.
b These assessments are completed at the end of the Acute Phase, which occurs between 4 and 12 weeks after starting study medications.
c These assessments are completed at week 36 or at the point of termination.
d Primary clinical ratings are HAM-D, DAS, SADS delusion and hallucination items, SSI, and CGI. In addition, the UKU side effects scale, Falls Log, and Concomitant
Medication Log will be completed at these visits.
e Baseline physical includes physical examination, screening blood tests (CBC, electrolytes, creatinine, AST, ALT, TSH, Vitamin B12, pregnancy test for
premenopausal women), urine drug screen, and EKG.
f Measures of anxiety, medical burden, and psychomotor change are the Hospital Anxiety and Depression Scale [37], Cumulative Illness Rating Scale [38], and
CORE [39], respectively.
g Cognitive evaluation includes: the IQCODE at baseline; and the MMSE, Immediate and Delayed Recall, Stroop, Trail Making, and Coding task [40,41] at the end of
the Stabilization Phase.
h Treatment resistance during the index episode of depression is measured with the Antidepressant Treatment History Form [42].
i The SF-36 [43] will be administered to: i) examine the association of acute and remitted psychotic depression with participants’ health-related quality of life, and
ii) explore the effect of continuation versus discontinuation of antipsychotic medication on participants’ health-related quality of life.
j The Best Guess Form is completed by participants at RCT termination, to determine, once the study is completed, whether they can guess treatment assignment
on a greater than chance basis; this will serve as an indicator of how well the study’s double-blind was preserved.
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fat [56]: BMI is an index of total body fat, whereas waist
circumference is a measure of abdominal obesity, which
is more specifically associated with cardiovascular risk
and metabolic syndrome than BMI. BMI and waist cir-
cumference are assessed at each study visit.
Analyses of antipsychotic weight gain in major depres-
sion can be confounded by depression-related weight
loss and weight restoration associated with recovery
from depression. Therefore, participants’ pre-morbid
weight is obtained, preferably from the patient’s primary
care physician’s records. Pre-morbid weight will be used
to calculate weight loss and weight restoration during
the index episode of depression, which will be taken in
to account in statistical analyses of weight change.Metabolic measures
Homeostatic model assessment (HOMA) [57], a meas-
ure of insulin resistance and the primary measure of gly-
cemic function in this study, will be calculated based on
an established formula, each time fasting glucose and in-
sulin are measured. HbA1c is a secondary measure of
glycemic function, to assess the longitudinal stability of
serum glucose levels during the course of the study.
Triglycerides and cholesterol (total, LDL, HDL) are also
measured.
Drug exposure
Pharmacokinetic changes associated with aging and
other individual factors can result in variability of drug
exposure, which in turn can result in differences in
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important piece of information when interpreting vari-
ability in treatment efficacy and adverse effects [58].
Blood is collected for determination of plasma sertraline
and olanzapine concentrations. The analytic strategy
will use population pharmacokinetics [59], which uses
nonlinear mixed effect modeling to identify intra- and
inter-individual sources of variability [60]. Variability
from the norm in drug concentrations can be determined
using sparse (between two and four) plasma samples per
patient [61].Pharmacogenetics
As with other psychiatric disorders, the pharmacologic
treatment of PD is associated with considerable treat-
ment variability. Pharmacogenetic findings have the po-
tential to result in more personalized treatment and
possibly preventive strategies. Because the number of
individuals recruited in a clinical trial is insufficient to
conduct a genome-wide association study, we employ a
candidate-gene approach to explore the following im-
portant issues: 1) genetic predictors of relapse of either
mood disorders or primary psychotic disorders are cur-
rently unknown: we therefore explore this issue in rela-
tion to this study; 2) several genetic polymorphisms have
been associated with antipsychotic-related weight gain
[62]. However, it is not known whether these polymor-
phisms predict reversal of weight gain following discon-
tinuation of the antipsychotic, an issue that we will
investigate; 3) there have been no published studies of
the pharmacogenetics of response or remission in PD.
We will therefore explore whether genetic polymor-
phisms that have been associated with antidepressant re-
sponse in non-psychotic depression, and antipsychotic
response and weight gain in schizophrenia, pertain to
PD. Finally, we participate in the National Institute of
Mental Health’s Human Genetics Initiative so that cell
lines, DNA, and genetic data from our very well cha-
racterized sample will be available to the wider scientific
community. For example, there is emerging evidence
that certain genes may confer risk for severe psychiatric
illness, as opposed to specific disorders [63,64]. The gen-
etic data from our study will provide scientists with the
unique opportunity to include persons with PD in ana-
lyses pertaining to these ‘susceptibility genes’.Data analysis
Randomization
We plan to randomize 88 participants to each of the two
treatment arms using a 1:1 allocation ratio, stratified by
age, remission vs. near remission status at randomiza-
tion, and site. In order to reduce the probability that a
disproportionate number of subjects are randomizedto any one level of the factors, a blocking strategy will
be used.
Primary hypothesis (H1)
This will be tested with a Cox proportional hazards
model based on all participants randomized to the RCT
that compares survival time (weeks from randomization
to relapse) across treatment groups. A subject’s survival
time will be classified as censored at the point of study
discontinuation (e.g., due to withdrawal of consent or
due to a severe intervening non-psychiatric medical
event) or at the end of follow-up, if relapse has not oc-
curred. Kaplan Meier survival curves will be used for de-
scriptive analyses of time to relapse. The Cox models
will include treatment group and the three aforemen-
tioned stratification variables. Treatment groups will be
compared on 5 variables at the time of randomization
that have the potential to be associated with risk of re-
lapse: anxiety, medical burden, executive dysfunction,
psychomotor change, and treatment resistance prior to
study entry; if the treatment groups differ significantly
on one or more of these variables (p ≤ .05) and the vari-
able in question is correlated with relapse (r > .30), the
variable will be included as a covariate in the Cox model.
The constant hazards assumption will be examined by
examining the incremental contribution of a treatment x
vulnerable period of relapse interaction (exploring the
possibility of higher risk in the first 3 months following
discontinuation).
Secondary hypotheses
H2 will be tested using separate mixed-effects linear re-
gression analyses for weight, cholesterol, and
triglycerides in the RCT. Subjects may be treated for
glucose or lipid abnormalities that develop during the
study. If a participant receives new treatment or a
change of treatment for hyperlipidemia or hyperglycemia
during the RCT, his/her pertinent metabolic data from
that point onwards will be excluded from the mixed
model, although the metabolic measures in question will
continue to be collected for safety analyses and reporting
to the Data Safety and Monitoring Board; based on data
from STOP-PD, we expect that fewer than 5% of
participants will have metabolic data censored for this
reason. We chose not to include these post-
randomization metabolic data as covariates in the mixed
model, because doing so could confound ‘cause and ef-
fect’ and result in a biased estimate of the treatment ef-
fect, thereby compromising the primary goal of the
analysis.
H3: Mixed-effects linear regression analysis will exam-
ine weight change from Acute Phase baseline.
Each statistical test for the primary and secondary hy-
potheses will involve a two-tailed alpha of 0.05.
Table 3 STOP-PD II: statistical power for survival analyses for hypothesis 1
Frequency of relapse for sertraline + placebo Frequency of relapse for sertraline + olanzapine Attrition Power
40% 15% 10% 0.95
40% 15% 15% 0.94
35% 15% 10% 0.84
35% 15% 15% 0.82
35% 10% 10% 0.98
35% 10% 15% 0.97
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Assumptions for power calculation for H1 We
propose 20% as the minimal clinically meaningful differ-
ence in relapse rates between olanzapine and placebo
over 36 weeks. A 20% difference would mean that 5
patients would need to be treated with olanzapine to
prevent 1 case of relapse. Based on the review of litera-
ture [14-16,65] and STOP-PD stabilization data, we esti-
mate that 15% of participants who are maintained on
sertraline plus olanzapine will have a relapse in the RCT.
A relapse rate of 35% in the sertraline plus placebo
group would therefore be consistent with the
hypothesized 20% difference between treatment groups.
Based on our previous experience of conducting studies
of the continuation and maintenance treatment of PD
[12,65,66], we predict that attrition during the RCT will
not exceed 10%. This attrition rate might appear to be
low, but this is because those subjects most vulnerable
to attrition will likely drop out in the phases prior to
randomization. Moreover, data pertaining to H1 will be
analyzed according to the intent to-treat principle, in
that each subject will be classified in a treatment group
based on randomized assignment without regard to
medication adherence. Thus, if a participant chooses to
discontinue one or both study medications in the RCT,
every effort is made to continue research assessments
for the entire course of randomized treatment or until
relapse (whichever comes first). The proposed sample
size will provide sufficient statistical power to detect
clinically meaningful differences in H1 (Table 3).Table 4 STOP-PD II: statistical power of mixed-effects linear r
Number of observations per subject Standardized effec
4 0.35
4 0.40
4 0.45
8 0.35
8 0.40
8 0.45Statistical power for H2 To account for attrition in H2,
the power analyses assumed we would collect at least 8
of 15 repeated assessments of weight and 4 of 5
measures of total cholesterol and triglycerides during the
RCT. The proposed design will have power ≥0.80 to de-
tect differential slopes that result in standardized
differences at endpoint ≥0.35 for weight and ≥0.40 for
triglycerides and total cholesterol (Table 4). To put these
in perspective, based on STOP-PD data, these effects
correspond to group differences as small as 4.9 lbs in
weight, 38 mg/dl in triglycerides, and 22 mg/dl in total
cholesterol.
Statistical power for H3 Power analyses for H3
assumed that we would collect at least 4 of the 6
planned assessments of weight during open-label treat-
ment. The proposed design will have power >0.80 to de-
tect differential slopes that result in a standardized
difference as small as 0.40 by the end of the open-label
phase (Table 4). To put this in context, of the
participants in STOP-PD who completed 12 weeks of
acute treatment, the younger group gained a mean 16.6
± 16.5 lbs and the older group gained a mean 10.7 ± 11.3
lbs; the standardized effect size for this weight difference
was 0.42.
Discussion
Antipsychotic discontinuation
Given the absence of data informing the continuation or
discontinuation of antipsychotic medication in remitted
PD, STOP-PD II provides the unique opportunity toegression analyses for hypotheses 2 and 3
t ICC = 0.50 Lipids ICC = 0.95 Weight
0.74 0.77
0.84 0.85
0.89 0.93
- 0.80
- 0.89
- 0.95
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opposed to switching antipsychotics) on antipsychotic-
related weight gain and metabolic effects. It is unclear
whether cessation of antipsychotic medication is asso-
ciated with complete reversal of weight gain and meta-
bolic effects, and if so how long this takes and whether
there is an age effect.
Accounting for depression-related weight change
PD can lead to considerable weight loss, in some
cases 25% or more of ideal body weight. Analysis of
antipsychotic-specific weight gain must account for
depression-related weight loss and the subsequent res-
toration of pre-morbid weight as depression improves.
Thus, we estimate weight prior to onset of the index
depressive episode, using objective measures of premorbid
weight (as opposed to self-report premorbid weight)
whenever possible.
Adult Age span approach
Studying adults across a wide age range has heuristic
value, given that older age increases the risk of PD. In
addition to the study’s secondary hypothesis and ex-
ploratory aim pertaining to an age effect on weight gain
and metabolic changes, we will conduct exploratory ana-
lyses focused on other age-related questions, such as
whether age effects the risk of relapse following anti-
psychotic discontinuation, and if so what are the clinical
or biological variables that moderate or mediate this
association.
Measurement of insight
The Resolution of Delusions Scale (RODS) (unpublished
data) was developed as a part of STOP-PD to assess a
subject’s level of insight into his/her delusion. In STOP-
PD II, we will explore whether lack of insight in to the
false nature of a previously held, but now remitted, de-
lusion increases the risk of relapse of PD, and if so
whether this is mediated through neuropsychological
processes.
Pharmacogenetics
STOP-PD II will be the first study to examine genetic
predictors of relapse and weight loss following discon-
tinuation of antipsychotic medication. These findings
have the potential to enhance the personalized care of
patients with PD.
Neuroimaging
Studies in schizophrenia suggest that antipsychotic
medication may cause alterations in brain structure [67],
but the observational nature of these studies is con-
founded by the potential effect of schizophrenia. The
placebo-controlled antipsychotic discontinuation designof STOP-PD II offers the unique opportunity to study
the specific effect of antipsychotic medication on brain
structure. The investigators will conduct a supplemental
study that will use magnetic resonance imaging during
the RCT to compare the effects of olanzapine and
placebo on brain structure and connectivity.
Conclusion
STOP-PD II addresses an issue of profound clinical im-
portance in the management of PD: what are the risks
and benefits of continuing antipsychotic medication in
remitted PD. The findings of this study will provide
clinicians with a much-needed evidence base to guide
the continuation treatment of one of the most disabling
and lethal psychiatric disorders.
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